RawData-MemoVigor-2-DB.xlsx

We studied the effectiveness of the antioxidant compound MemoVigor 2 in the treatment of idiopathic tinnitus. This was a randomized double-blind placebo-control clinical trial. 104 patients belonged to the intervention group and 100 patients to the placebo group. We examined all the participants in the beginning of the study, and after 3 months. After a detailed otological history and clinical examination, we performed the following tests: a. Audiometry/Tympanometry. b. Specific measures of tinnitus perception. c. Tinnitus Questionnaires: Tinnitus Handicap Inventory; mini Tinnitus Questionnaire; Patients' Global Impression of Change. The following raw data of the subjects of the intervention group (N=104) and of the placebo group (N=100) are included: Sex-Age-Duration of Tinnitus- Hearing Thresholds at 0.25 kHz, 0.5 kHz, 1 kHz, 2 kHz, 4 kHz, 6 kHz, and 8 kHz, for the Right Ears on the initial session - Hearing Thresholds at 0.25 kHz, 0.5 kHz, 1 kHz, 2 kHz, 4 kHz, 6 kHz, and 8 kHz, for the Left Ears on the initial session – Tinnitus Pitch, Loudness at Dominant Frequency, Loudness at 1 kHz, Minimal masking level (MML), maskability and Residual Inhibition (RI) on the initial session - Hearing Thresholds at 0.25 kHz, 0.5 kHz, 1 kHz, 2 kHz, 4 kHz, 6 kHz, and 8 kHz, for the Right Ears on the post-3-month session - Hearing Thresholds at 0.25 kHz, 0.5 kHz, 1 kHz, 2 kHz, 4 kHz, 6 kHz, and 8 kHz, for the Left Ears on the post-3-month session – Tinnitus Pitch, Loudness at Dominant Frequency, Loudness at 1 kHz, Minimal masking level (MML), maskability and Residual Inhibition (RI) on the post-3-month session – Tinnitus Handicap Inventory (initial and post-3-month) – Mini Tinnitus Questionnaire (initial and post-3-month) –Patient’s Global Impression of Change.